Peralta-Garcia, AlejandroTorrens Fontanals, MarionaStepniewski, Tomasz Maciej, 1988-Grau-Expósito, JudithPerea, DavidAyinampudi, VikramWaldhoer, MariaZimmermann, MirjamBuzón, María J.Genescà, MeritxellSelent, Jana2022-01-282022-01-282021Peralta-Garcia A, Torrens-Fontanals M, Stepniewski TM, Grau-Expósito J, Perea D, Ayinampudi V, Waldhoer M, Zimmermann M, Buzón MJ, Genescà M, Selent J. Entrectinib-A SARS-CoV-2 inhibitor in Human Lung Tissue (HLT) cells. Int J Mol Sci. 2021;22(24):13592. DOI: 10.3390/ijms2224135921422-0067http://hdl.handle.net/10230/52352Since the start of the COVID-19 outbreak, pharmaceutical companies and research groups have focused on the development of vaccines and antiviral drugs against SARS-CoV-2. Here, we apply a drug repurposing strategy to identify drug candidates that are able to block the entrance of the virus into human cells. By combining virtual screening with in vitro pseudovirus assays and antiviral assays in Human Lung Tissue (HLT) cells, we identify entrectinib as a potential antiviral drug.application/pdfeng© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).info:eu-repo/semantics/articlehttp://dx.doi.org/10.3390/ijms222413592COVID-19SARS-CoV-2Drug repurposingViral cell entry assaysVirtual screeninginfo:eu-repo/semantics/openAccess